Can-Fite adds 18% as compassionate use of liver cancer therapy expands

Aug. 23, 2022 7:29 AM ETCan-Fite BioPharma Ltd. (CANF)By: Dulan Lokuwithana, SA News Editor1 Comment

model of a human liver made of paper and a stethoscope on a blue background. concept timely diagnosis of liver diseases

Irina Petrakova/iStock via Getty Images

  • The shares of Israeli biotech Can-Fite BioPharma (NYSE:CANF) climbed ~18% in pre-market trading Monday after the company announced that Romania approved its liver disease candidate Namodenoson for compassionate use in advanced liver cancer.
  • Previously Israel also approved Namodenoson for advanced liver cancer patients who underwent therapy for several years.
  • CANF has launched a pivotal Phase III study to evaluate the oral therapy as a second-line treatment in advanced hepatocellular carcinoma.
  • The trial, open for recruitment in Israel, the U.S., and five European countries, is expected to support regulatory submissions for approval for Namodenoson in the U.S. and Europe.
  • “We are committed to providing Namodenoson, with an excellent safety profile and strong efficacy in this patient population in clinical trials to date, to fulfill an urgent unmet medical need,” CEO of Can-Fite (CANF) Pnina Fishman remarked.
  • CANF shares surged in December after the company announced that a Namodenoson-treated patient showed a complete response in an extension of a mid-stage trial for hepatocellular carcinoma.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.